In addition to scoring higher than 99 percent of stocks in the Healthcare sector, ARDX’s 84 overall rating means the stock scores better than 84 of all stocks. Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARDX in relation to earlier this year. Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Cidara Therapeutics, and CymaBay Therapeutics.
- One share of ARDX stock can currently be purchased for approximately $4.08.
- The technique has proven to be very useful for finding positive surprises.
- A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
- Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development.
ARDX’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of go markets overview the overall market. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity.
Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations.
According to TipRanks, Arce has an average return of 9.8% and a 42.20% success rate on recommended stocks. Ardelyx’s stock was trading at $2.85 at the beginning of the year. Since then, ARDX stock has increased by 43.2% and is now trading at $4.08. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Style is an investment factor that has a meaningful impact on how to open a brokerage account investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Shares in Ardelyx Inc. plummeted more than 70% in after-hours trading Monday, following the biopharmaceutical company’s that the Food and Drug Administration appears unlikely to approve a drug for dialysis patients.
Stock Money Flow
Shares of Ardelyx Inc. rocketed 75.4% on heavy volume toward a 16-month high in premarket trading Thursday, after an advisory panel of the U.S. Food and Drug Administration voted that benefits of the biopharmaceutical com… The 84 rating InvestorsObserver gives to Ardelyx Inc (ARDX) stock puts it near the top of the Healthcare sector.
The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Upgrade to MarketBeat All Access to add more stocks eur usd trading to your watchlist. One share of ARDX stock can currently be purchased for approximately $4.08. Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise.
Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA. 6 Wall Street research analysts have issued twelve-month price targets for Ardelyx’s stock. On average, they predict the company’s stock price to reach $8.25 in the next twelve months. This suggests a possible upside of 102.2% from the stock’s current price.
Analyst Expectations for Ardelyx’s Future
Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Ardelyx Stock Skyrockets After Its Kidney Disease Drug Gets a Surprise Step Closer to FDA Approval
We’d like to share more about how we work and what drives our day-to-day business. Compare
ARDX’s historical performance
against its industry peers and the overall market. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.
Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company’s product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program.
The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions.
What is Ardelyx Inc’s stock style?
The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.